摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

磷,(3-甲氧基丙基)三苯基-,碘化 | 133622-76-1

中文名称
磷,(3-甲氧基丙基)三苯基-,碘化
中文别名
——
英文名称
(3-methoxypropyl)triphenyl-phosphonium iodide
英文别名
3-methoxypropyl(triphenyl)phosphanium;iodide
磷,(3-甲氧基丙基)三苯基-,碘化化学式
CAS
133622-76-1
化学式
C22H24OP*I
mdl
——
分子量
462.31
InChiKey
RQRZBYKBHVTOCY-UHFFFAOYSA-M
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.02
  • 重原子数:
    25
  • 可旋转键数:
    7
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.18
  • 拓扑面积:
    9.2
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

点击查看最新优质反应信息

文献信息

  • Heterocyclic-substituted alkanamides as therapeutic compounds
    申请人:Speedel Experimenta AG
    公开号:EP1958666A1
    公开(公告)日:2008-08-20
    Use of compounds of the general formula (I) and pharmaceutically acceptable salt thereof, in which R1 and R2 have the definitions illustrated in detail in the description, as beta-secretase, cathepsin D, plasmepsin II and/or HIV protease inhibitors.
    使用一般式(I)及其药用盐的化合物,其中R1和R2的定义在描述中详细说明,作为β-分泌酶、半胱蛋白酶D、血浆蛋白酶II和/或HIV蛋白酶抑制剂。
  • Chlorophenylalkoxyalkyl compounds
    申请人:Hoffmann-La Roche Inc.
    公开号:US05399689A1
    公开(公告)日:1995-03-21
    The present invention is concerned with novel chlorophenylalkoxyalkyl compounds of the general formula ##STR1## wherein R denotes an alkyl residue with 1 to 12 carbon atoms; n is a whole number of 2 to 7, ring A denotes trans-1,4-cyclohexylene or 1,4-phenylene; m is either 0 or 1; ring B is trans-1,4-cyclohexylene, 1,4-phenylene in which optionally one CH group or two non-adjacent CH groups is/are replaced by nitrogen or, when m stands for 1, also trans-1,3-dioxane-2,5-diyl; Y.sup.1 and Y.sup.2 each independently represent a single covalent bond or --CH.sub.2 CH.sub.2 --; and X denotes hydrogen, fluorine or chlorine, their manufacture, liquid crystalline mixtures which contain these compounds, their production and use for electro-optical purposes.
    本发明涉及一种新型的氯苯基烷氧基烷基化合物,其一般式为##STR1##其中,R表示具有1到12个碳原子的烷基残基;n是2到7的整数;环A表示反-1,4-环己烯基或1,4-苯基;m为0或1;环B为反-1,4-环己烯基,1,4-苯基,其中一个CH基团或两个不相邻的CH基团可以被氮代替,或者当m为1时,也可以是反-1,3-二氧杂环戊烷-2,5-二基;Y1和Y2各自独立地表示单一共价键或-CH2CH2-;X表示氢、。本发明还涉及这些化合物的制造、含有这些化合物的液晶混合物、其制备和用于电光目的的使用。
  • Heterocyclic-Substituted Alkanamides Useful as Renin Inhibitors
    申请人:Herold Peter
    公开号:US20080176947A1
    公开(公告)日:2008-07-24
    Compounds of the general formula (I) in which the meanings of the substituents R 1 and R 2 are as stated in claim 1 , have renin-inhibiting properties and can be used as medicines.
    通式(I)中,取代基R1和R2的含义如权利要求1所述的化合物具有抑制肾素的性质,可用作药物。
  • 5-Amino-4-Hydroxy-7-(Imidazo [1,2-A] Pyridin-6-Ylmethyl)-8-Methyl-Nonamide Derivatives and Related Compounds as Renin Inhibitors for the Treatment of Hypertension
    申请人:HEROLD Peter
    公开号:US20100063087A1
    公开(公告)日:2010-03-11
    Compounds of the general formula (I) or its salt or a compound in which one or more atoms are replaced by their stable, nonradio-active isotopes, in particular its pharmaceutically acceptable salt; in which X is —CH 2 —; R is a mono- to tetra-substituted, mono- or bicyclic, unsaturated heterocyclic radical having 1 to 4 nitrogen atoms, R 2 is C 1-6 alkyl or C 3-6 cycloalkyl; R 3 is independently of one another H, C 1-6 alkyl, C 1-6 alkoxycarbonyl or C 1-6 alkanoyl; R 4 is C 2-6 alkenyl, C 1-6 alkyl, unsubstituted or substituted aryl-C 1-6 alkyl or C 3-8 cycloalkyl; R 5 is -L m -R ; L is C 1-6 alkylene which is optionally substituted by 1-4 halogen, or a linker: formula (II) n=0, 1 or 2; m=0 or 1; R 6 is a radical composed of 2 cyclic systems selected from bicyclo[x.y.z]alkyl, spiro[o.p]alkyl, mono- or bioxabicyclo[x.y.z]alkyl or mono- or bioxaspiro[o.p]alkyl, all of which may be substituted by 1-3 substituents selected from C 1-6 alkyl, C 1-6 alkoxy, cyano, halogen, C 1-6 alkoxy- C 1-6 alkyl, hydroxy-C 1-6 alkyl or dialkylamino, or if m=0: is also saturated C 3-8 heterocyclyl which comprises 1-2 oxygen atoms, substituted by 1-3 substituents selected from C 1-6 alkyl, C 1-6 alkoxy, cyano, halogen, C 1-6 alkoxy-C 1-6 alkyl, hydroxy-C 1-6 alkyl or dialkylamino, or if m=1: is also saturated C 3-8 heterocyclyl which comprises 1-2 oxygen atoms, optionally substituted by 1-3 substituents selected from C 1-6 alkyl, C 1-6 alkoxy, cyano, halogen, C 1-6 -alkoxy-C 1-6 alkyl, hydroxy-C 1-6 alkyl or dialkylamino; have renin-inhibiting properties and can be used as medicines for the treatment of hypertension.
    通式(I)的化合物或其盐或其中一个或多个原子被其稳定的非放射性同位素替换的化合物,特别是其药学上可接受的盐;其中X为-CH2-;R为1至4个氮原子的单取代、双取代、三取代或四取代的单环或双环不饱和杂环基,R2为C1-6烷基或C3-6环烷基;R3独立地为H、C1-6烷基、C1-6烷氧羰基或C1-6酰基;R4为C2-6烯基、C1-6烷基、未取代或取代的芳基-C1-6烷基或C3-8环烷基;R5为-Lm-R;L为C1-6烷基,可选地被1-4个卤素取代,或为连接基:通式(II)n=0、1或2;m=0或1;R6为由自行选择的2个环系统组成的基,所述环系统选择自双环[x.y.z]烷基、螺[O.P]烷基、单环或双氧杂双环[x.y.z]烷基或单环或双氧杂螺[O.P]烷基,所有这些基都可以被1-3个取代基所取代,所述取代基选择自C1-6烷基、C1-6烷氧基、基、卤素、C1-6烷氧基-C1-6烷基、羟基-C1-6烷基或二烷基基,或如果m=0:还是饱和的C3-8杂环基,其中包括1-2个氧原子,被1-3个取代基所取代,所述取代基选择自C1-6烷基、C1-6烷氧基、基、卤素、C1-6烷氧基-C1-6烷基、羟基-C1-6烷基或二烷基基,或如果m=1:还是饱和的C3-8杂环基,其中包括1-2个氧原子,可选地被1-3个取代基所取代,所述取代基选择自C1-6烷基、C1-6烷氧基、基、卤素、C1-6烷氧基-C1-6烷基、羟基-C1-6烷基或二烷基基;具有抑制肾素的性质,可用作治疗高血压的药物。
  • 5-amino-4-hydroxy-7-(imidazo [1,2-A] pyridin-6-ylmethyl)-8-methyl-nonamide derivatives and related compounds as renin inhibitors for the treatment of hypertension
    申请人:Novartis AG
    公开号:US08071651B2
    公开(公告)日:2011-12-06
    Compounds of the general formula (I) or its salt or a compound in which one or more atoms are replaced by their stable, nonradio-active isotopes, in particular its pharmaceutically acceptable salt; in which X is —CH2—; R is a mono- to tetra-substituted, mono- or bicyclic, unsaturated heterocyclic radical having 1 to 4 nitrogen atoms, R2 is C1-6alkyl or C3-6cycloalkyl; R3 is independently of one another H, C1-6alkyl, C1-6alkoxycarbonyl or C1-6alkanoyl; R4 is C2-6alkenyl, C1-6alkyl, unsubstituted or substituted aryl-C1-6alkyl or C3-8cycloalkyl; R5 is -Lm-R6; L is C1-6alkylene which is optionally substituted by 1-4 halogen, or a linker: formula (II) n=0, 1 or 2; m=0 or 1; R6 is a radical composed of 2 cyclic systems selected from bicyclo[x.y.z]alkyl, spiro[o.p]alkyl, mono- or bioxabicyclo[x.y.z]alkyl or mono- or bioxaspiro[o.p]alkyl, all of which may be substituted by 1-3 substituents selected from C1-6alkyl, C1-6alkoxy, cyano, halogen, C1-6alkoxy-C1-6alkyl, hydroxy-C1-6alkyl or dialkylamino, or if m=0: is also saturated C3-8heterocyclyl which comprises 1-2 oxygen atoms, substituted by 1-3 substituents selected from C1-6alkyl, C1-6alkoxy, cyano, halogen, C1-6alkoxy-C1-6alkyl, hydroxy-C1-6alkyl or dialkylamino, or if m=1: is also saturated C3-8heterocyclyl which comprises 1-2 oxygen atoms, optionally substituted by 1-3 substituents selected from C1-6alkyl, C1-6alkoxy, cyano, halogen, C1-6-alkoxy-C1-6alkyl, hydroxy-C1-6alkyl or dialkylamino; have renin-inhibiting properties and can be used as medicines for the treatment of hypertension.
    通式(I)或其盐或其中一个或多个原子被它们的稳定的非放射性同位素所替代的化合物,特别是其药学上可接受的盐;其中X是—CH2—;R是一个单取代至四取代、单环或双环、不饱和的杂环基团,含1至4个氮原子;R2是C1-6烷基或C3-6环烷基;R3是独立的H、C1-6烷基、C1-6烷氧羰基或C1-6酰基;R4是C2-6烯基、C1-6烷基、未取代或取代的芳基-C1-6烷基或C3-8环烷基;R5是-Lm-R6;L是可选地被1-4个卤素取代的C1-6烷基,或连接物:通式(II),n=0、1或2;m=0或1;R6是由选自双环[x.y.z]烷基、螺[ο.p]烷基、单或双氧杂双环[x.y.z]烷基或单或双氧杂螺[ο.p]烷基的2个环系统组成的基团,所有这些基团都可以被选自C1-6烷基、C1-6烷氧基、基、卤素、C1-6烷氧基-C1-6烷基、羟基-C1-6烷基或二烷基基的1-3个取代基所取代,或如果m=0:还包括由1-2个氧原子组成、被选自C1-6烷基、C1-6烷氧基、基、卤素、C1-6烷氧基-C1-6烷基、羟基-C1-6烷基或二烷基基的1-3个取代基所取代的饱和C3-8杂环基团,或如果m=1:还包括由1-2个氧原子组成、可选地被选自C1-6烷基、C1-6烷氧基、基、卤素、C1-6烷氧基-C1-6烷基、羟基-C1-6烷基或二烷基基的1-3个取代基所取代的饱和C3-8杂环基团;具有抑制肾素的性质,可用作治疗高血压的药物。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫